ICEF 16
Alternative Names: ICEF-16Latest Information Update: 30 Aug 2021
At a glance
- Originator Innovacell Biotechnologie GmbH
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Faecal incontinence
Most Recent Events
- 26 Aug 2021 Preclinical trials in Faecal Incontinence in European Union (IM) (Innovacell Biotechnology GmbH pipeline, August 2021)
- 26 Aug 2021 Preclinical trials in Faecal Incontinence in Japan (IM) (Innovacell Biotechnology GmbH pipeline, August 2021)
- 26 Aug 2021 Preclinical trials in Faecal Incontinence in USA (IM) (Innovacell Biotechnology GmbH pipeline, August 2021)